“…2 Multiple clinical pathways have been developed incorporating biomarkers, functional testing, and noninvasive angiography, all of which have high success rates. 5 Although patients are no longer admitted, direct costs remain high ($2226-$3168) regardless of modality, driven to a great degree by length of stay in the hospital. 3 In order to reduce the cost, the focus should be on three critical factors-reduce the number of people requiring chest pain pathways, reduce utilization of advanced imaging, or decrease length of hospital stay.…”